Rein Therapeutics, Inc. Income Statement
RNTX|9 years of annual SEC 10-K data (FY2017-FY2025)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 9 fiscal years. All figures from audited SEC 10-K filings.
Rein Therapeutics, Inc. reported $0 in revenue and $63M in net loss for FY2025.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -9.18 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| SG&A Expense | $13.9M | $11.4M | $9.7M | $9.6M | $9.3M | $12.3M | $13.5M | $8.8M | $5.1M |
| R&D Expense | $14.2M | $4.0M | $18.0M | $17.0M | $11.2M | $17.7M | $18.4M | $14.2M | $7.8M |
| Operating Income | -$65.1M | -$16.3M | -$27.6M | -$26.6M | -$20.5M | -$30.0M | -$31.9M | -$23.0M | -$12.9M |
| Income Tax | -$1.5M | $0 | $0 | $0 | $0 | $0 | $0 | $0 | - |
| Net Income | -$62.9M | -$15.7M | -$27.3M | -$27.3M | -$21.2M | -$29.4M | -$31.5M | -$22.6M | -$12.9M |
| EPS (Basic) | -$3.51 | -$3.42 | -$6.02 | -$5.89 | - | - | - | - | - |
| EPS (Diluted) | -$3.51 | -$3.42 | -$6.02 | -$5.89 | -$0.61 | -$1.20 | -$2.14 | -$3.04 | -$32.31 |
| Shares Outstanding | 21.7M | 4.9M | 4.5M | 4.5M | 43.8M | 27.8M | 14.7M | 14.7M | 432.4K |